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veloped pneumothorax. Patients who developed pneumo-
thorax had a higher median number of pleural adhesions, 2.7 
(IQR 1.9–4) compared to 1.7 (1–2.7) adhesions in the group 
without pneumothorax ( p < 0.01). The PAS in the group with 
pneumothorax was higher compared to that in the group 
without: 14.3 (12.4–24.1) versus 6.7 (3.7–11.2) ( p < 0.01). A 
threshold PAS of  ≥ 12 was associated with a higher risk of 
pneumothorax (OR 13.0, 95% CI 3.1–54.9). A score <12 did 
not rule out the occurrence of pneumothorax.  Conclusion: 
A higher number of pleural adhesions on HRCT with a sub-
sequent higher PAS in the treated lung is associated with a 
higher occurrence of pneumothorax after EBV treatment.
 © 2017 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Bronchoscopic lung volume reduction is a rapidly de-
veloping treatment option for emphysema patients with 
severe hyperinflation  [1–6] . Following careful selection of 
the right patients, lung volume reduction may lead to 
clinically relevant improvements in lung function, qual-
ity of life, and exercise performance  [7–13] . Of the avail-
able techniques, treatment with endobronchial valves 
 Keywords 
 Pneumothorax · Lung volume reduction · Chronic 
obstructive pulmonary disease · Bronchoscopy · 
Emphysema · Valves · Hyperinflation 
 Abstract 
 Background: Pneumothorax after bronchoscopic lung vol-
ume reduction using one-way endobronchial valves (EBVs) 
in patients with advanced emphysema occurs in approxi-
mately 20% of patients. It is not well known which factors 
predict the development of pneumothorax.  Objective: To 
assess whether pleural adhesions on pretreatment high-res-
olution computed tomography (HRCT) scans are associated 
with pneumothorax occurrence after EBV treatment.  Meth-
ods: HRCT scan analyses were performed on all patients who 
received EBV treatment in a randomized controlled trial. 
Three blinded readers scored adhesions by number and by 
measuring the longest axis of each pleural adhesion in the 
treated lung. The Pleural Adhesion Score (PAS) was calcu-
lated by adding 1 point for each small pleural lesion (<1 mm), 
5 points for each medium-sized lesion (1–5 mm), and 10 
points for each large lesion (>5 mm).  Results: The HRCT 
scans of 64 treated patients were assessed, of whom 14 de-
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(EBVs) in patients without interlobar collateral ventila-
tion shows the best results  [14–18] . However, pneumo-
thorax after EBV treatment is a common adverse event, 
occurring in about 20% of patients  [19] . Its severity varies, 
from just an asymptomatic radiologic abnormality, pneu-
mothorax ex vacuo, to life-threatening tension pneumo-
thorax  [20, 21] . A reliable risk assessment for pneumo-
thorax is therefore an important unmet need in this new 
treatment area. Identifying which patients are at higher 
risk may help informing them better about their individ-
ual risks and lead to longer planned observation time in 
the hospital after treatment.
 It is not well known what causes the development of 
pneumothorax after EBV treatment  [19] . A possible ex-
planation is that the pneumothorax is caused by preex-
isting adhesions between the treated lung and the pari-
etal pleura (see  Fig. 1 for a thoracoscopic view). Large 
volume shifts after successful EBV treatment and subse-
quent repositioning of the lung could subsequently rup-
ture the visceral pleura. Whether this explanation is val-
id remains unknown, since pleural adhesions have not 
been systemically assessed from this point of view. In-
deed, an earlier study showed that larger changes in vol-
ume after treatment were associated with a higher risk of 
pneumothorax, an observation that fits the hypothesis 
that pleural adhesions present a risk  [19] . However, that 
study did not assess whether a larger volume of the target 
lobe is a risk factor. Other possible mechanisms involve 
visceral pleural rupture in target and nontarget lobe sur-
faces, rupture of the bulla, or a mechanism unrelated to 
pleural surface rupture but due to a mismatch between 
the lung and the thoracic cage, causing pneumothorax ex 
vacuo. Pneumothorax related to procedure and postpro-
cedure management might occur due to high mechani-
cal ventilation pressures, Chartis measurements, and 
heavy coughing. Furthermore, specific emphysema phe-
notype, heterogeneity of emphysema, and emphysema 
severity might influence the pneumothorax risk after 
valve therapy.
 The objective of this study was to assess whether pleu-
ral adhesions on pretreatment high-resolution computed 
tomography (HRCT) scans are associated with pneumo-
thorax after EBV treatment. We hypothesized that pleu-
ral adhesions are associated with the occurrence of pneu-
mothorax in lungs treated with EBV. In addition, we hy-
pothesized that larger volumes of the target lobes are also 
associated with the occurrence of pneumothorax.
 Materials and Methods 
 Study Design 
 The pretreatment HRCT scans of all patients who had received 
EBV treatment in the STELVIO trial  [14] were analyzed. In this 
trial, 64 patients with severe emphysema and hyperinflation were 
treated with valves in the absence of collateral flow between the 
target lobe and the ipsilateral nontarget lobe between June 2011 
and November 2014. The inclusion criteria included a postbron-
chodilator forced expiratory volume in 1 s (FEV 1 ) <60% of pre-
dicted, a total lung capacity (TLC) >100% of predicted, and a re-
sidual volume (RV) >150% of predicted. Furthermore, the HRCT 
scan needed to demonstrate a target lobe with a (near-)complete 
interlobar fissure. The main exclusion criterion was evidence of 
collateral ventilation in the target lobe during Chartis measure-
ment. Patients were randomized to receive immediate EBV treat-
ment or standard care. The standard care group was treated with 
EBV after 6 months of follow-up. In the current analyses, the data 
of both groups were combined. Details of the trial, including its 
design, ethics, informed consent, and inclusion/exclusion criteria 
have been published previously  [14] . All patients provided in-
formed consent and confidentiality was maintained.
 All patients were observed after treatment in the hospital for at 
least 1 day. Chest X-rays were performed directly after treatment, 
before discharge, and when indicated in case of symptoms to assess 
the presence of pneumothorax. The occurrence of pneumothorax 
was registered until 1 year after treatment for all patients.
 Scoring of the Occurrence of Pleural Adhesions 
 To identify pleural lesions, the baseline chest HRCT scan was 
assessed by three blinded readers (two pulmonologists and a spe-
cialized chest radiologist). The readers were not informed about 
the later occurrence of pneumothorax during reading. They in-
dividually and independently assessed the number, location, and 
size of pleural adhesions in the treated lung. They were instruct-
ed to report only lesions with pleural involvement; peripheral 
lung lesions without pleural involvement were therefore not re-
ported.


































   
   
   
   
   
   
   
   
   



























 Fig. 2. Examples of pleural adhesions. Top 
row: Three different-sized pleural adhe-
sions. Bottom row: red indicates the size of 
each adhesion. The lesion on the left was 
measured as <1 mm, resulting in a PAS of 
1 point, the middle one was measured as 
1–5 mm, resulting in 5 points, and the le-
sion on the right was measured as >5 mm, 
resulting in 10 points. 











Female sex 67% 62% 86% 0.10
Age, years 59 (53 – 65) 59 (53 – 64) 62 (52 – 68) 0.39
Body mass indexb 24 (22 – 26) 24 (22 – 26) 23 (22 – 25) 0.71
Number of pack-years 35 (23 – 45) 35 (22 – 45) 33 (24 – 45) 0.66
Lung function
Forced expiratory volume in 1 s
Value, L 0.79 (0.61 – 0.94) 0.88 (0.64 – 1.01) 0.71 (0.53 – 0.83) 0.05
Percent of predicted value 28 (24 – 36) 28 (25 – 37) 27 (23 – 32) 0.16
Forced vital capacity
Value, L 2.62 (2.00 – 3.21) 2.65 (2.01 – 3.41) 2.53 (1.85 – 3.03) 0.29
Percent of predicted value 79 (65 – 93) 79 (65 – 92) 76 (65 – 94) 0.81
Residual volume
Value, L 4.34 (3.82 – 5.04) 4.34 (3.81 – 4.89) 4.32 (3.85 – 5.29) 0.69
Percent of predicted value 214 (195 – 240) 209 (193 – 232) 224 (200 – 254) 0.20
Total lung capacity
Value, L 7.21 (6.70 – 8.48) 7.25 (6.62 – 8.60) 7.19 (6.80 – 7.84) 0.81
Percent of predicted value 131 (124 – 141) 130 (124 – 136) 141 (128 – 144) 0.61
Residual volume/total lung capacity
Ratio, % 58 (53 – 68) 58 (51 – 69) 62 (56 – 67) 0.07
Arterial blood gas
PaCO2, kPac 5.0 (4.7 – 5.6) 5.0 (4.7 – 5.6) 5.2 (4.7 – 6.1) 0.38
PaO2, kPac 9.3 (8.0 – 10.2) 9.3 (8.0 – 10.2) 9.0 (7.5 – 10.7) 0.96
Exercise performance
Distance on 6-min walk test, m 356 (300 – 427) 383 (305 – 431) 325 (275 – 407) 0.13
Quality of life
St. George’s Respiratory Questionnaire total score, pointsd 58 (47 – 64) 58 (49 – 64) 57 (47 – 66) 0.96
Modified Medical Research Council scale, pointse 3 (2 – 3) 3 (2 – 3) 3 (2 – 3) 0.14
Clinical COPD Questionnaire total score, pointsf 2.6 (2.2 – 3.3) 2.6 (2.1 – 3.4) 2.8 (2.3 – 3.2) 0.81
Values are presented as median (IQR) unless indicated otherwise. COPD, chronic obstructive pulmonary disease; PaCO2, partial 
pressure of carbon dioxide; PaO2, partial pressure of oxygen. a Between-group difference (nonparametric). b Weight in kg divided by the 
square of the height in m2. c Measurements were performed while the patient was breathing ambient air. d Scores range from 0 to 100, 
with higher scores indicating worse quality of life. e Scores range from 0 to 4, with higher scores indicating a greater severity of dyspnea. 
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 Pleural Adhesion Score 
 It was hypothesized that larger lesions produce more traction 
on the pleura and therefore increase the pneumothorax risk. 
Therefore, the size of a pleural adhesion was measured and catego-
rized into an arbitrary score: 1 point for each small pleural lesion 
(<1 mm), 5 points for each medium-sized lesion (1–5 mm), and 10 
points for each large lesion (>5 mm) ( Fig. 2 ). This system was de-
veloped before the assessment of the pleural lesions by the readers 
was completed. Afterwards, all scores in an individual patient were 
cumulated into the so-called Pleural Adhesion Score (PAS). The 
PAS was also expressed per treated and untreated lobes. Finally, 
for each patient an average PAS of all three assessors was calcu-
lated.
 Volume Measurements 
 Quantitative volume measurements of the treated and untreat-
ed lobes were performed on the baseline inspiratory HRCT using 
the Thirona Lung Quantification CT software version 15.01 (Thi-
rona, Nijmegen, The Netherlands)  [14, 22, 23] .
 Analyses 
 To assess differences between the groups of patients with and 
without pneumothorax, independent-sample Mann-Whitney U 
tests were performed. To derive a threshold for the PAS, a receiver 
operating characteristic (ROC) curve with a sensitivity and speci-
ficity of at least 0.8 was used. The ORs were calculated using logis-
tic regression. Variation between the readers was analyzed with the 
intraclass correlation coefficient. A  p value <0.05 was considered 
significant. SPSS version 22 (IBM, USA) was used for the statistical 
analyses.
 Results 
 The HRCTs of the 64 patients were all assessed by 
three blinded readers. Fourteen patients (22%) developed 
pneumothorax after EBV treatment and 50 patients 
(78%) did not. Ten patients required chest tube drainage, 
4 patients with pneumothorax ex vacuo did not. The 
baseline characteristics of both groups are reported in  Ta-
ble  1 . No statistically significant differences were ob-
served between the two groups; nevertheless, the pneu-
mothorax group tended to a slightly lower absolute FEV 1 
( p = 0.05) and more hyperinflation (RV/TLC ratio) ( p = 
0.07). Due to the low number of pneumothoraxes no sep-
arate analysis was performed on subgroups with different 
types of pneumothorax.
 Pleural Lesions 
 Participants with a higher number of pleural adhe-
sions more often developed pneumothorax: patients who 
developed pneumothorax had a median number of 2.7 
(IQR 1.9–4) adhesions compared to 1.7 (1–2.7) adhesions 
in patients without pneumothorax ( p < 0.01) ( Fig. 3 ;  Ta-
ble 2 ). The Pearson correlation between small lesions and 
pneumothorax was  r = 0.22, and large lesions had a cor-
relation with pneumothorax of  r = 0.29.
 No significant difference between the groups was 
found when separately assessing the number of pleural 
adhesions in the treated lobe. The patients who developed 








































 Fig. 3. Total number of pleural adhesions in the target lung by 
group based on the occurrence of pneumothorax after one-way 
endobronchial valve treatment. Each triangle represents the mean 
of the observed number of pleural adhesions in a single participant 
by three assessors. The Mann-Whitney U test was used to assess 
the difference between the groups. The horizontal line represents 
the median. 
 Fig. 4. Pleural Adhesion Score in the target lung based on the oc-
currence of pneumothorax after one-way endobronchial valve 
treatment. Each triangle represents the mean Pleural Adhesion 
Score of the three assessors. The Mann-Whitney U test was used 
to assess the difference between the groups. The horizontal line 



















   
   
   
   
   
   
   
   
   



























lobe than those who did not develop pneumothorax – 
1 (0.6–1.5) and 0.5 (0–1.3), respectively,  p = 0.04.
 Pleural Adhesion Score 
 The PAS (median and IQR) in the group with pneu-
mothorax was 14.3 (12.4–24.1) compared to 6.7 (3.7–
11.2) in the group without ( p < 0.01) ( Table 2 ;  Fig. 4 ). Ev-
ery extra point on the PAS was associated with a higher 
pneumothorax risk – an OR of 1.2 (95% CI 1.1–1.3,  p < 
0.01) per point. From the ROC curve, an area under the 
curve of 0.83 was calculated ( Fig. 5 ). From the ROC curve 
a threshold PAS of  ≥ 12 was derived to achieve a sensitiv-
ity and specificity of both 0.8. A score above this threshold 
showed a markedly higher risk for pneumothorax (OR 
13.0, 95% CI 3.1–54.9). However, 3 patients with a PAS 
<12 developed pneumothorax after treatment. The nega-
tive predictive value of the PAS was 93%, the positive pre-
dictive value was 48%. Analysis of the individual PAS of 
the three readers showed an intraclass correlation coef-
ficient of 0.46.
 Volumes 
 No difference in volumes of the individual target lobes 
or target lobe to total lung ratio was detected between the 
groups ( Table 2 ). In 51 patients it was possible to measure 
the change in total lung volume after EBV treatment 
with CT volume measurements. Eight of these developed 
pneumothorax. No difference between the groups in tar-
get lobar volume reduction was detected; however, this 
finding should be interpreted with care since we could 
not measure in 6 of the pneumothorax patients.
 Location 
 Thirty-six patients were treated in the upper lobes, of 
whom 9 developed pneumothorax (25%), whereas 5 out 
of the 28 lower-lobe-treated patients developed pneumo-















 Table 2. Results of the analysis










Treated lobe 1.3 (0.7 – 2) 1.0 (0.3 – 2) 1.5 (1.0 – 2.7) 0.06
Untreated lobe 0.7 (0.3 – 1.3) 0.5 (0 – 1.3) 1 (0.6 – 1.5) 0.04
Total treated lung 1.8 (1 – 3) 1.7 (1 – 2.7) 2.7 (1.9 – 4.0) <0.01
Pleural Adhesion Score
Treated lobe 5.3 (2 – 10) 4.8 (1.5 – 7.9) 10 (8.3 – 19.5) <0.01
Untreated lobe 1.7 (0.3 – 5.7) 1.7 (0 – 5.7) 4 (1.4 – 6.8) 0.04
Total treated lung 7.3 (4.3 – 13.7) 6.7 (3.7 – 11.2) 14.3 (12.4 – 24.1) <0.01
Lobar volumes
Treated lobe volume, mL 1,773 (1,446 – 2,145) 1,790 (1,465 – 2,150) 1,720 (1,378 – 2,093) 0.66
Treated lobe volume, percentage of 
total treated lung volume 53 (47 – 61) 53 (48 – 62) 53 (48 – 60) 0.88
Values are presented as median (IQR). a Between-group difference (nonparametric). b Mean number observed by the three readers.
 Fig. 5. Receiver operating characteristic curve of the Pleural Adhe-
sion Score for pneumothorax. Solid line, Pleural Adhesion Score; 
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 Our analysis of the presence of pleural adhesions on 
the pretreatment inspiratory HRCT scans of all patients 
treated with one-way EBVs in the STELVIO trial  [14] 
showed that a higher number and larger size of pleural 
adhesions in the treated lung was associated with a high-
er occurrence of pneumothorax after treatment.
 EBV treatment has been shown to be a very effective 
treatment for patients with severe emphysema without 
collateral ventilation  [14] . However, both the STELVIO 
trial  [14] and the BeLieVeR-HIFi  [16] trial demonstrated 
that about 20% of treated patients develop pneumothorax 
early after treatment. Although pneumothorax after EBV 
treatment is nowadays considered to be part of the treat-
ment, for these patients, the occurrence of pneumothorax 
can be a serious complication associated with higher 
morbidity, prolonged hospital admissions, chest tube in-
sertions, additional bronchoscopies, treatment failure, 
and rarely even death  [14, 16, 19, 20] . Better patient selec-
tion and prediction of pneumothorax risk is therefore of 
great importance. Our results showed that pleural adhe-
sions assessment may identify patients at risk. The design 
of this study allows only preliminary conclusions and as 
a next step, the PAS should be prospectively studied, per-
haps combined with video-assisted thoracoscopy results 
and multivariate analysis. In our view, a high PAS and 
therefore a higher pneumothorax risk could lead to a 
number of measures to be taken. First, a prolonged obser-
vation period in the hospital could be considered, al-
though it remains difficult to predict when it is safe to 
discharge patients. Second, a more intensive observation 
with repeated chest X-rays could be considered. Third, 
bed rest and cough reduction might be attractive, as Her-
zog et al.  [24] demonstrated that such a regimen reduces 
the occurrence of early pneumothorax from 25 to 5%. 
Even more speculative is the performance of prophylactic 
interpleural drainage in patients at high risk for life-
threatening pneumothoraxes or surgical removal of the 
adhesions prior to treatment. Finally, the risk of a higher 
PAS could be discussed between the physician and the 
patient who is a candidate for bronchoscopic volume re-
duction treatment.
 This study observed a higher PAS in the treated com-
pared with the untreated lobe. Both study design and 
sample size, however, did not allow reliable analysis of 
associations between the severity of the pneumothorax 
and the distribution of the pleural adhesions. However, 
one would expect that a more severe pneumothorax with 
a larger air leak is caused by lesions in the untreated lobe.
 Next to the pleural adhesions, we hypothesized that 
the volume of the treated lobe at baseline on HRCT could 
correlate with pneumothorax occurrence. In the analysis 
by Gompelmann et al.  [19] , change in volume after treat-
ment of the target was related to pneumothorax risk. The 
present study could not assess the change in lung volume 
after the procedure in relation with pneumothorax occur-
rence. From a post hoc view one might argue that this 
change in volume is more associated with pneumothorax 
occurrence; however, we aimed to predict the risk before 
starting the treatment. At baseline, in our study the me-
dian target lobar volume was not significantly different 
between the groups, an observation that persisted when 
target lobar volume was corrected for total lung volume. 
Furthermore, we observed a trend that patients in the 
group who developed pneumothorax were more often 
treated in the upper lobes and had a lower FEV 1 and more 
hyperinflation. This could reflect more destruction and 
perhaps additional vulnerability of the tissue.
 Previous data about systemic scoring of pleural adhe-
sions are not available, perhaps because it was thought 
not to have clinical consequences. Only one paper assess-
ing pleural adhesions as a minor endpoint amongst oth-
ers was recently published  [25] . The authors found adhe-
sions to be slightly protective against pneumothorax. 
However, these adhesions were not scored systematically 
and were analyzed by a single reader only. Also since 
pleural adhesions had not been systematically examined 
before as a risk factor for pneumothorax, we had to de-
velop a new scoring system. Taking into account the re-
sults of our study, the PAS appeared to be a tool to esti-
mate this risk, with an area under the curve of 0.83. How-
ever, the PAS was the average score of three independent 
readers, who demonstrated only moderate agreement. 
On the other hand, this interobserver agreement is com-
parable to the interobserver agreements of other radio-
logical scores, for instance in interstitial lung diseases 
and fissure assessment  [26–28] . Further optimization in 
quantifying pleural adhesions is clearly needed in such a 
way that only one reader is needed to produce reliable 
measurements, or even better to develop quantitative CT 
analysis software to measure this.
 Another interesting opportunity is to assess the pleura 
in more detail, especially in relation with the surrounding 
tissue, e.g., by targeted ultrasound. Cassanelli et al.  [29] 
already showed that ultrasound is able to detect pleural 
adhesions. Future studies might investigate whether pa-
tients with more peripheral destruction in panlobular or 
paraseptal emphysema and adjacent pleural adhesions 



















   
   
   
   
   
   
   
   
   



























tients with a more centrilobular emphysema. Another re-
lated question that could be raised is whether the com-
pleteness and speed of the development of atelectasis of 
the treated lobe is associated with the occurrence of pneu-
mothorax, or whether the presence of adhesions per se is 
more important.
 Conclusion 
 Our study showed that more extensive pleural adhe-
sions are associated with higher risk of pneumothorax 
 after treatment with EBV. These data, if prospectively 
 validated, have the potential of significantly influencing 
treatment decisions and algorithms.
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